AK Medical Holdings Ltd. (1789) AI Stock Analysis

• Market Cap: HK$7.53B
• Dividend Yield: 1.07%
• Average Volume (3M): 7.50M
• Price to Earnings (P/E): 25.2
• Beta (1Y): 1.22
• Revenue Growth: 20.19%
• EPS Growth: 45.54%
• Country: HK
• Employees: 950
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): 0.13
• Shares Outstanding: 1,122,695,800
• 10 Day Avg. Volume: 12,016,867
• 30 Day Avg. Volume: 7,499,513
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$7.50
• Price Target Upside: 11.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: HK$7.50 ▲(11.61% Upside)

AK Medical Holdings Ltd. demonstrates strong financial performance, particularly in revenue growth and balance sheet stability, which are key strengths. Technical analysis shows positive price momentum, but caution is advised due to overbought signals. Valuation metrics suggest the stock might be overvalued, which could limit upside potential.

AK Medical Holdings Ltd. Business Overview & Revenue Model

Company Description

AK Medical Holdings Ltd. (1789) is a leading provider in the orthopedic medical device industry, primarily focusing on the research, development, manufacturing, and sales of orthopedic implants. The company's core products include joint prostheses, spinal implants, and other related surgical instruments. AK Medical is recognized for its innovative 3D-printed orthopedic implants and its commitment to advancing medical technology to improve patient outcomes.

How the Company Makes Money

AK Medical Holdings Ltd. generates revenue through the sale of its orthopedic implants and related surgical instruments. The company's key revenue streams include direct sales to hospitals, clinics, and healthcare providers, as well as distribution partnerships with medical device distributors. AK Medical's earnings are significantly bolstered by its proprietary 3D printing technology, which sets it apart in the competitive medical device sector. The company also engages in strategic partnerships and collaborations with research institutions and medical professionals to enhance product development and expand its market reach.

AK Medical Holdings Ltd. Financial Statement Overview

Summary

AK Medical Holdings Ltd. shows strong revenue growth and profitability with a solid balance sheet. However, cash flow inconsistencies present some risk, requiring better management to support future growth.

Income Statement

AK Medical Holdings Ltd. has demonstrated strong revenue growth over the years, with a significant increase from 2023 to 2024. The gross profit margin has remained healthy, with a slight improvement. Net profit margin has also seen an upward trend, indicating efficient cost management. EBIT and EBITDA margins are stable, showcasing effective operational management.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio, indicating low financial leverage. A high equity ratio reflects strong capitalization. The return on equity is solid, showcasing effective use of shareholder funds. Overall, the company is financially stable with a strong equity base and manageable liabilities.

Cash Flow

Cash flow from operations has been inconsistent, with a significant drop in the latest year. The free cash flow has also been volatile, reflecting potential challenges in managing capital expenditures and investments. However, the company's ability to generate operating cash flow relative to net income indicates potential for improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.35B	1.09B	1.05B	761.44M	1.04B
Gross Profit	808.19M	674.49M	636.43M	499.19M	714.53M
EBITDA	371.66M	323.34M	322.87M	184.33M	438.41M
Net Income	273.93M	182.10M	204.77M	92.62M	314.01M
Balance Sheet
Total Assets	3.34B	3.00B	2.77B	2.61B	2.53B
Cash, Cash Equivalents and Short-Term Investments	1.05B	726.67M	1.04B	841.13M	901.49M
Total Debt	99.39M	84.20M	38.78M	41.56M	26.85M
Total Liabilities	697.21M	611.12M	530.73M	573.73M	484.13M
Stockholders Equity	2.64B	2.39B	2.24B	2.03B	2.04B
Cash Flow
Free Cash Flow	289.11M	-162.14M	121.20M	100.39M	115.47M
Operating Cash Flow	451.07M	33.94M	242.92M	176.62M	205.26M
Investing Cash Flow	-393.35M	-318.15M	-82.29M	-297.10M	-356.41M
Financing Cash Flow	-39.43M	-14.02M	-36.80M	-100.70M	611.74M

AK Medical Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1789, the sentiment is Positive. The current price of 6.72 is above the 20-day moving average (MA) of 6.44, above the 50-day MA of 6.14, and above the 200-day MA of 5.36, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 60.79 is Neutral, neither overbought nor oversold. The STOCH value of 37.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1789.

AK Medical Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	75 Outperform	HK$7.53B	25.24	10.92%	1.07%	20.19%	45.54%
1302	73 Outperform	HK$8.94B	37.98	6.49%	―	0.87%	-18.05%
1858	67 Neutral	HK$8.58B	43.12	4.39%	0.94%	-32.05%	-54.47%
Sector *	60 Neutral	HK$18.08B	4.77	-4.00%	3.35%	9.59%	-23.62%
2190	59 Neutral	€7.40B	66.69	3.22%	0.48%	45.82%	―
9996	55 Neutral	€5.75B	―	-10.43%	―	36.76%	42.89%

AK Medical Holdings Ltd. Corporate Events

AK Medical Holdings Schedules Board Meeting to Review Interim Results

AK Medical Holdings Ltd. has announced a board meeting scheduled for August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The board will also discuss the potential payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.

AK Medical Holdings Announces Change in Share Registrar

AK Medical Holdings Limited has announced a change in its Hong Kong Share Registrar and Transfer Office, effective from August 1, 2025. The new registrar will be Tricor Investor Services Limited, and all applications for registration and transfer of shares should be directed to them from this date. This change is part of the company’s ongoing efforts to streamline its operations and improve shareholder services.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.

AK Medical Holdings Ltd. Updates Nomination Committee to Enhance Governance

AK Medical Holdings Ltd. announced changes in its Nomination Committee, effective June 25, 2025, in response to amendments in the Listing Rules and Corporate Governance Code. These changes include the appointment of Dr. Li Shu Wing David as the new chairman and Ms. Zhang Bin as a member, aiming to enhance board effectiveness and diversity, thereby strengthening corporate governance practices.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.

AK Medical Holdings Ltd. Announces Successful AGM Resolutions

AK Medical Holdings Ltd. announced the results of its Annual General Meeting held on June 18, 2025, where all proposed resolutions were passed. Key decisions included the approval of the audited financial statements for 2024, the declaration of a final dividend, re-election of directors, re-appointment of KPMG as auditors, and granting mandates to the directors for share repurchase and issuance. These resolutions reflect the company’s continued focus on financial transparency, shareholder returns, and strategic flexibility in managing its share capital.

The most recent analyst rating on (HK:1789) stock is a Buy with a HK$5.27 price target. To see the full list of analyst forecasts on AK Medical Holdings Ltd. stock, see the HK:1789 Stock Forecast page.